Healthcare
for Life^®

The 1315 team invested in Colorescience at a pivotal time, leading our Series C round of financing and unlocking substantial growth. Together we refined the unique brand promise of multi-functional, science-backed products tailored for everyday use. Colorescience benefitted from active thought partnership, analytical support, brand advocacy, and access to healthcare networks.

Mary Fisher

CEO of Colorescience

1315 Capital was more than an investor — they were true partners. Their financial support, strategic insight, and support of our vision enabled Biocoat to grow from a small specialty player into a market leading hydrophilic coating company for medical devices in the U.S. in under four years. Together, we achieved a transformational outcome.

Jim Moran

CEO of Biocoat

1315 Capital’s investment and early strategic involvement were critical to the founding of Onkos Surgical. We successfully carved out assets from a strategic as part of a shared vision of addressing an underserved market in musculoskeletal oncology and complex orthopedics. This approach not only accelerated our entry into the market but also created meaningful long-term value for patients, providers, and investors.

Patrick Treacy

CEO of Onkos Surgical

I founded Centurion Service Group in 2001 and had built it into the country’s largest medical equipment auction house. I had many investors interested in the business but ultimately chose 1315 Capital due to their healthcare expertise and their buy-in to my vision for the business. Through 1315 Capital’s investment, I was able to generate significant liquidity through a majority recapitalization and I retained a meaningful rollover stake in the business as well as staying on as CEO.

Erik Tivin

CEO of Centurion Service Group

1315 Capital quickly got up to speed on the nuances of our business, and the specific opportunities and issues we faced. We had an exceedingly difficult international transaction we were working on to buy out a foreign shareholder that involved months of complex negotiation. 1315 Capital completed the transaction and turned out to be the perfect partner we needed, as we were able to leverage their healthcare industry experience and network to help navigate the company to a successful exit.

Matt Oristano

CEO of Reaction Biology